LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Rocket Pharmaceuticals Inc

Closed

SectorHealthcare

3.07 10.83

Overview

Share price change

24h

Current

Min

2.77

Max

3.17

Key metrics

By Trading Economics

Income

-1M

-61M

EPS

-0.56

Employees

299

EBITDA

-380K

-58M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+288.09% upside

Dividends

By Dow Jones

Next Earnings

1 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-540M

298M

Previous open

-7.76

Previous close

3.07

News Sentiment

By Acuity

100%

0%

368 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Rocket Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

27 May 2025, 12:05 UTC

Major Market Movers

Rocket Pharmaceuticals Shares Down as Trial Patient Dies of Complications

28 Jun 2024, 14:25 UTC

Major Market Movers

Rocket Pharmaceuticals Shares Slide After FDA Rejects Kresladi

Peer Comparison

Price change

Rocket Pharmaceuticals Inc Forecast

Price Target

By TipRanks

288.09% upside

12 Months Forecast

Average 10.75 USD  288.09%

High 30 USD

Low 2 USD

Based on 17 Wall Street analysts offering 12 month price targets forRocket Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

17 ratings

9

Buy

7

Hold

1

Sell

Technical Score

By Trading Central

6.21 / 7.86Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

No Evidence

Sentiment

By Acuity

368 / 380 Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.